The planned 230,000 square-foot plant is the healthcare company's latest step in a 10-year plan to modernize and expand its distribution network. ...

For many years, Americans have paid the highest prices anywhere in the world for prescription drugs. They paid far more, 10 times, 13 times, 15 times more than other countries for the exact same product. A major reason is that the American consumers have been subsidizing research and development costs for the entire planet.They put all of that on us and yet they were the beneficiaries to. So, it's being changed as of today. The United States had just 4% of the world's population and consumers, only 13% of a ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced a historic agreement with the Trump Administration that will ensure U.S. patients pay lower prices for their prescription medicines while strengthening America's role as the global leader in biopharmaceutical innovation. In response to the four points covered in the President's July 31st letter, Pfizer has voluntarily agreed to implement measures designed to ensure Americans receive comparable drug prices to those available in o. ...

Welcome to Market Catalyst. I'm Julie Hyman. We are 30 minutes into the US trading day. Let's get to the three market catalysts we're watching this hour. First up, the clock is ticking for the government to stay open or shut down. We're going to break down the economic implications of a shutdown. Plus, consumer confidence data crossing the wire. We'll have details ahead and interpretation. And Nike is set to report earnings after the bell. We'll get a read on its turnaround and look at the broader winners a ...

PRESS RELEASE AB SCIENCE ANNOUNCES A SLIGHT DELAY IN THE PUBLICATION OF ITS 2025 HALF-YEAR FINANCIAL REPORT THE COMPANY WILL PUBLISH ITS HALF-YEAR FINANCIAL REPORT FOR 2025 ON OCTOBER 10, 2025, AT THE LATEST Paris, September 30 2025, 6.30pm CET AB Science SA (Euronext - FR0010557264 - AB) today announced that it has postponed the publication of its financial report for the first half of 2025, initially scheduled for 30 September 2025, to give the auditors time to complete their audit work. The Company will ...

Americans will soon be able to buy prescription drugs directly from the federal government, according to the White House. On Tuesday, President Donald Trump announced the launch of a direct-to-consumer website where consumers could purchase discounted drugs. It will be called "TrumpRx.""It increases transparency; in many instances, prices are 80% lower than they are today," Chris Klomp, the Director of Medicare and Deputy Administrator of CMS, said during the announcement. "No more Canadian detours to purc ...

About this content About Oliver Haill Oliver has been writing about companies and markets since the early 2000s, cutting his teeth as a financial journalist at Growth Company Investor with a focusing on AIM companies and small caps, before a few years later becoming a section editor and then head of research. He joined Proactive after a couple of years freelancing, where he worked for the Financial Times Group, ITV, Press Association, Reuters sports desk, the London Olympic News Service, Rugby World Cup ...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX), while raising the price target to $143 from $86, implying an upside potential of over 200% from the current levels. This confidence follows the company’s successful approval of Palsonify. The firm notes that Palsonify, an oral SST2 agonist designed for acromegalic adults who aren’t fit for ...

Key Takeaways Novo Nordisk cut its 2025 outlook as Wegovy and Ozempic face slower uptake and rising competition.CagriSema hit key weight loss goals in late-stage studies, with a regulatory filing planned for 2026.Novo Nordisk is also advancing cagrilintide, Amycretin, and adding assets via acquisitions and licensing.Novo Nordisk (NVO) has achieved tremendous commercial success with its blockbuster semaglutide products, Wegovy (for obesity) and Ozempic (for diabetes). However, the company’s growth trajectory ...

投资评级与市场反应 - 高盛首次覆盖Innoviva公司并给予卖出评级 目标股价为17美元 [1] - 该报告导致公司股价在盘前交易中下跌超过1% [1] 公司核心战略与历史表现 - 公司成功实施将来自GSK呼吸药物Breo Ellipta和Anoro Ellipta特许权使用费的现金流进行再投资的战略 [1] - 该再投资战略主要投向公司的重症监护和传染病产品组合 [1] - 自2021年以来 该战略推动公司股价相对XBI指数表现出80%的超额收益 [1] 主要风险与未来挑战 - 公司面临2031年特许权专利到期的风险 [2] - GSK特许权使用费预计将占2025年收入的60% 该部分收入将面临专利独占权失效的压力 [2] - GSK特许权使用费同时面临《通货膨胀削减法案》带来的相关压力 [2] 业务板块与管线压力 - 专利到期风险给公司传染病治疗领域带来更大压力 该领域商业环境仍具挑战性 [3] - 公司关键的2026年管线产品上市预计将面临仿制药标准疗法的竞争 [3] - 该2026年管线产品可能无法充分利用公司现有的商业平台 [3]